Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)
This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
First received: June 6, 2011
Last updated: November 18, 2013
Last verified: November 2013
This was a retrospective, chart review, observational study to assess the effect of MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg [Hyzaar(R)]) treatment for a period of at least three months on serum uric acid levels.
||Observational Model: Cohort
Time Perspective: Retrospective
||A Retrospective Survey to Evaluate the Impact of Hyzaar on Uric Acid in the Management of Hypertensive Patients in Normal Practice
Primary Outcome Measures:
Secondary Outcome Measures:
- The Percentage of Patients With Hyperuricemia [ Time Frame: Baseline and Month 3 ] [ Designated as safety issue: No ]
Hyperuricemia was defined as SUA >6.6mg/dL in females and >7.7mg/dL in males.
- Diastolic Blood Pressure (DBP) [ Time Frame: Baseline and Month 3 ] [ Designated as safety issue: No ]
DBP at baseline and month 3.
- Systolic Blood Pressure (SBP) [ Time Frame: Baseline and Month 3 ] [ Designated as safety issue: No ]
SBP at baseline and month 3.
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||August 2010 (Final data collection date for primary outcome measure)
Participants with hypertension who had been treated with MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg) for at least three months
|Ages Eligible for Study:
||20 Years to 75 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Data from 33 physicians from different levels of hospitals were invited to provide information on patients who received MK-0954A and had pre- and post-treatment serum uric acid and lipid profile reports during the study period. Each physician could provide up to 30 clinical charts of patients matching the inclusion criteria for the study.
- Had been treated with diuretic or angiotensin-receptor blockers (ARBs) 2 weeks before initiated treatment with MK-0954A 50/12.5 mg
- Serum creatinine >2 mg/dL
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
No Contacts or Locations Provided
No publications provided
||Merck Sharp & Dohme Corp.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 6, 2011
|Results First Received:
||August 2, 2011
||November 18, 2013
||Taiwan: Institutional Review Board
Keywords provided by Merck Sharp & Dohme Corp.:
Essential hypertension Uric acid Retrospective Hyzaar
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on August 28, 2014
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs